Enveric Biosciences, Inc.
ENVB
$5.32
$0.224.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.53% | 17.41% | |||
| Depreciation & Amortization | -2.23% | 1.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.08% | -25.61% | |||
| Operating Income | -17.08% | 25.61% | |||
| Income Before Tax | -17.11% | 25.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -17.11% | 25.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.11% | 25.62% | |||
| EBIT | -17.08% | 25.61% | |||
| EBITDA | -17.50% | 26.04% | |||
| EPS Basic | 43.36% | 7.15% | |||
| Normalized Basic EPS | 44.39% | 48.64% | |||
| EPS Diluted | 43.36% | 7.15% | |||
| Normalized Diluted EPS | 44.39% | 48.64% | |||
| Average Basic Shares Outstanding | 110.63% | 44.80% | |||
| Average Diluted Shares Outstanding | 110.63% | 44.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||